Logo

BCTXZ

BriaCell Therapeutics Corp. Warrant

BCTXZ

BriaCell Therapeutics Corp. Warrant • NASDAQ
$0.37 ▲ 9.96% (+0.03)
Market Cap $2.53 M
52w High $0.38
52w Low $0.32
Dividend Yield 0%
P/E 0
Volume 61
Outstanding Shares 6.78M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $0 $8.555M ▲ $-8.092M ▼ 0% $4.19 ▲ $-8.037M ▼
Q3-2025 $0 $6.328M ▼ $-6.127M ▲ 0% $-1.64 ▲ $-6.161M ▲
Q2-2025 $0 $7.169M ▲ $-6.291M ▼ 0% $-2.33 ▼ $-7.143M ▼
Q1-2025 $0 $5.153M ▼ $-5.802M ▼ 0% $-0.22 ▼ $-5.126M ▲
Q4-2024 $0 $5.768M $-1.214M 0% $0 $-7.143M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $17.866M ▲ $21.65M ▲ $4.316M ▼ $17.334M ▲
Q3-2025 $12.46M ▲ $17.002M ▲ $5.061M ▼ $12.415M ▲
Q2-2025 $5.014M ▼ $9.364M ▼ $6.137M ▼ $3.603M ▼
Q1-2025 $5.792M ▲ $10.414M ▲ $6.701M ▼ $4.043M ▲
Q4-2024 $862.089K $5.872M $8.557M $-2.382M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2025 $-8.164M ▼ $-8.132M ▼ $-7.391M ▼ $13.557M ▼ $-1.966M ▼ $-8.132M ▼
Q3-2025 $-6.225M ▲ $-7.163M ▼ $-105K ▼ $14.714M ▲ $7.447M ▲ $-7.163M ▼
Q2-2025 $-6.338M ▼ $-5.92M ▲ $-75K $5.217M ▼ $-778.611K ▼ $-5.92M ▲
Q1-2025 $-5.829M ▼ $-6.955M ▼ $-75K ▲ $11.96M ▲ $4.93M ▲ $-6.955M ▼
Q4-2024 $-1.249M $-4.036M $-456.801K $4.419M $-73.605K $-4.493M

Five-Year Company Overview

Income Statement

Income Statement BriaCell is still a pure research-stage biotech, with no product sales and no meaningful revenue over the past several years. The company consistently reports operating and net losses, which is typical for a small clinical‑stage biotech funding trials and development rather than selling approved drugs. Losses have been fairly steady rather than rapidly worsening, but there is no sign yet of a move toward profitability because everything depends on eventual trial success and potential approvals, which remain in the future.

Balance Sheet

Balance Sheet The balance sheet is very small and simple: modest assets, mostly cash, and no debt. The lack of borrowings reduces financial strain, but the overall asset and equity base is thin, which means a limited cushion against setbacks. In practical terms, BriaCell appears dependent on raising new capital over time to keep funding its pipeline until it reaches a commercial stage or secures partners.

Cash Flow

Cash Flow Cash flow reflects a classic early‑stage biotech profile: cash is flowing out steadily to cover R&D and operations, with no offsetting inflows from products. Free cash flow has been consistently negative, but spending levels look modest rather than aggressive, and there is essentially no heavy investment in physical assets. This pattern underscores ongoing reliance on external financing and the importance of managing the cash burn relative to future funding options.

Competitive Edge

Competitive Edge BriaCell operates in a very competitive cancer immunotherapy space but is trying to differentiate with an “off‑the‑shelf yet personalized” whole‑cell vaccine approach. Its lead breast cancer therapy has early data and a regulatory fast‑track status that suggest potential clinical relevance, including signals that compare favorably with an established competitor in difficult‑to‑treat patients. The company’s patent portfolio, long‑dated protection, and focus on scalable, cost‑conscious manufacturing provide some strategic advantages, but it still faces intense competition from far larger, well‑funded oncology players and the high bar of late‑stage clinical trials.

Innovation and R&D

Innovation and R&D Innovation is the core of BriaCell’s story: its Bria‑IMT platform and the Bria‑OTS family aim to combine broad immune activation with practical, scalable personalization using HLA‑matching. The pipeline extends beyond breast cancer into prostate, lung, and melanoma programs, with next‑generation versions designed to amplify immune signaling. The company is also experimenting with AI‑enabled drug discovery through collaborations, which could eventually broaden its technology base. All of this R&D is promising but high‑risk: value creation depends heavily on positive trial readouts, regulatory progress, and the ability to translate scientific promise into real‑world treatments.

Summary

Overall, BCTXZ represents exposure to a very early‑stage, high‑risk biotech that is still in the development and trial phase, with no revenue and ongoing operating losses. Financially, BriaCell runs a lean balance sheet with no debt but relies on external funding to support continued negative cash flow. Strategically, its strength lies in a differentiated immunotherapy platform, encouraging early clinical signals, regulatory recognition, and a broad, patent‑protected pipeline. At the same time, the company faces substantial scientific, clinical, regulatory, and financing uncertainty, and outcomes will hinge on pivotal trial results and the ability to secure partners or commercialization pathways over the coming years.